Home › Therapeutic areas › Oncology › Gastric Cancer
Gastric Cancer (10 companies)
Companies with an active program in Gastric Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| ARTV | Artiva Biotherapeutics | Oncology | 1 | — | $203M | 6 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $186M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $477M | 7 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | — | 13 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $4.55B | 17 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $52.8M | 8 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $106M | 7 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
No companies match.